Enanta Pharmaceuticals Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Enanta Pharmaceuticals Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- ENTA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001177648
Board of directors
-
Bruce L. A. Carter · DirectorSince 2023
-
Jay R. Luly · Director · President and CEOSince 2023
-
Kristine Peterson · DirectorSince 2023
-
Lesley Russell · DirectorSince 2023
-
Mark G. Foletta · DirectorSince 2023
-
Terry Vance · DirectorSince 2023
-
Yujiro S. Hata · DirectorSince 2023
Chief executives
Jay R. Luly
· President and CEO
Dates unknown
Board connections
3 of this board's directors also sit on 5 other boards.
- via Mark G. Foletta
- via Kristine Peterson
- via Mark G. Foletta
- via Yujiro S. Hata
- via Kristine Peterson
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $183,167
- 9 sales by 7 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 8, 2026 | Rottinghaus Scott T. Officer (Chief Medical Officer) | Shares withheld for tax | −1,467 | $13.34 | $19,570 |
| Feb 12, 2026 | Kowalsky Matthew Paul Officer (Chief Legal Officer) | Grant or award | +1,318 | — | — |
| Feb 12, 2026 | Luu Brendan Officer (Chief Business Officer) | Grant or award | +1,575 | — | — |
| Feb 12, 2026 | Kieffer Tara Lynn Officer (Chief Product Strategy Officer) | Grant or award | +1,575 | — | — |
| Feb 12, 2026 | Rottinghaus Scott T. Officer (Chief Medical Officer) | Grant or award | +1,650 | — | — |
| Feb 12, 2026 | Or Yat Sun Officer (Chief Scientific Officer) | Grant or award | +1,650 | — | — |
| Feb 12, 2026 | Jay R. Luly Director, Officer (President and CEO) | Grant or award | +4,800 | — | — |
| Feb 12, 2026 | Kowalsky Matthew Paul Officer (Chief Legal Officer) | Grant or award | +4,175 | — | — |
| Feb 12, 2026 | Luu Brendan Officer (Chief Business Officer) | Grant or award | +4,987 | — | — |
| Feb 12, 2026 | Kieffer Tara Lynn Officer (Chief Product Strategy Officer) | Grant or award | +4,987 | — | — |
| Feb 12, 2026 | Rottinghaus Scott T. Officer (Chief Medical Officer) | Grant or award | +5,225 | — | — |
| Feb 12, 2026 | Or Yat Sun Officer (Chief Scientific Officer) | Grant or award | +5,225 | — | — |
| Feb 12, 2026 | Jay R. Luly Director, Officer (President and CEO) | Grant or award | +15,200 | — | — |
| Feb 12, 2026 | Kowalsky Matthew Paul Officer (Chief Legal Officer) | Shares withheld for tax | −1,902 | $14.25 | $27,104 |
| Feb 12, 2026 | Luu Brendan Officer (Chief Business Officer) | Shares withheld for tax | −3,257 | $14.25 | $46,412 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.